开始
Hemostemix Inc
做多

$HMTXF witnesses the return of intellectual property to the comp

29

In the very recent news release, the company announces that it possesses the entirety of its intellectual property, including all HS 12-01 Phase II clinical path information and all authentic information from Hemostemix Israel.
InvestorRelations-1
更多:
Fundamental AnalysistradingtradingsignalstradingstrategiesTrend Analysis

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。
Fundamental AnalysistradingtradingsignalstradingstrategiesTrend Analysis
InvestorRelations-1
更多:

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。